TOP TIERMARKET NEWSWIRE
News & sentiment

QUINCE THERAPEUTICS (QNCX) — News & AI sentiment

QUINCE THERAPEUTICS (QNCX) news roundup. 12 stories aggregated over the last 30 days. Average 30-day sentiment is 53.2/100. No insider transactions filed in the last 90 days. No congressional trade disclosures in the last 90 days. Data shown on this page is delayed 4 hours. Real-time access — including the live wire, real-time alerts, the live S&P 500 heatmap, and the AI Top Trades long/short board — is available with a Top Tier Newswire Pro subscription.

Public view, delayed 4h. For real-time news, alerts, AI sentiment and the long/short AI Top Trades board:Open in the live terminal →
24h stories
0
7d stories
0
30d stories
12
avg sentiment 53.2/100
Insider net (90d)
$0
0 buys · 0 sells
Congress (90d)
0
0 buys · 0 sells

QNCX news in the last 24 hours, 7 days, 30 days and 90 days

How much QNCX coverage the wire captured in each window, with the average AI sentiment across those stories. Counts are of stories that have cleared the 4-hour public delay.

Time windowQNCX storiesAvg AI sentimentRead
Last 24 hours0—no coverage
Last 7 days0—no coverage
Last 30 days1253.2/100QNCX headlines →
Last 90 days3352.8/100QNCX headlines →

Latest stories on QNCX

Oct 19
Oct 9
Oct 9
Oct 9
Oct 9
Oct 9
Oct 6
Oct 6
Oct 2
Oct 2
Citizens reiterates Quince Therapeutics stock rating on therapy potential
Investing.com Analyst Ratings56 · neutralanalyst
Sep 29
Sep 29
Rodman & Renshaw initiates Quince Therapeutics stock with buy rating
Investing.com Analyst Ratings61 · neutralanalyst
Sep 24
Sep 24
Sep 22
Sep 22
Sep 17
Sep 14
Sep 4
Sep 3
Sep 3
Aug 27
Aug 20
Aug 20
Quince Therapeutics stock rating reiterated by Cantor Fitzgerald
Investing.com Analyst Ratings50 · neutralanalyst
Aug 18
Open QNCX in the live Top Tier Newswire terminal for real-time stories, sentiment, insider + congress alerts, and the AI Top Trades long/short board.Start a 1-day free trial →